Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

What this study is testing ClinicalTrials.gov NCT02811484 ↗

Description as written by the study sponsor.

The purpose of this study is to see what the effects of using one or two additional diabetes drugs (dapagliflozin and exenatide-LAR) are on blood sugar levels in patients who are taking insulin. This research study is being done to investigate which of these commonly-used medications, medication combinations or increasing insulin dose is better.

Treatments tested

• Exenatide-LAR plus Dapagliflozin placebo also known as Bydureon, Farxiga Drug

  Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.

• Exenatide-LAR plus Dapagliflozin also known as Bydureon, Farxiga Drug

  Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.

• Insulin Titration also known as Lantus, Levemir, Novolog, Lispro Drug

  Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%

• Behavioral Therapy Behavioral

  Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.